Skip to main content

Medical Oncology

Ausgabe 5/2024

Inhalt (37 Artikel)

Original Paper

Design and evaluation of a multiepitope vaccine for pancreatic cancer using immune-dominant epitopes derived from the signature proteome in expression datasets

Sooram Banesh, Nupoor Patil, Vihadhar Reddy Chethireddy, Arnav Bhukmaria, Prakash Saudagar

Original Paper

The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma

Qing-Qing Liu, Xiang-Xu Wang, Hongchen Ji, Qiong-Yi Dou, Hong-Mei Zhang

Original Paper

Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing

Kai Xiong, Yuqi Fang, Boyuan Qiu, Chaotao Chen, Nanchang Huang, Feiyuan Liang, Chuangming Huang, Tiantian Lu, Li Zheng, Jinmin Zhao, Bo Zhu

Original Paper

Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation

Mainuddin, Anoop Kumar, Ratneshwar Kumar Ratnesh, Jay Singh, Shweta Dumoga, Nitin Sharma, Amulya Jindal

Open Access Original Paper

Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach

Bahar Kartal, Farika Nur Denizler-Ebiri, Mustafa Güven, Filiz Taşpınar, Hande Canpınar, Sedat Çetin, Tuğçe Karaduman, Serkan Küççüktürk, Javier Castresana, Mehmet Taşpınar

Open Access Original Paper

Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer

Anne-Dorthe Mosgaard Knudsen, Mikala Wej Modvig, Marianne Vogsen, Annette Raskov Kodahl

Original Paper

YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis

Yuanben Wang, Yulin Cao, Ying Chen, Han Cheng, Zhiang Liu, Mengna Wang, Yuyang Feng, Bojian Fei, Kaisa Cui, Zhaohui Huang

Original Paper

Regulation of hippo signaling mediated apoptosis by Rauvolfia tetraphylla in triple-negative breast cancer

B. Balavaishnavi, M. Kamaraj, T. G. Nithya, P. Santhosh, S. GokilaLakshmi, Mohammed Rafi Shaik

Original Paper

Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy

Jiejian Chen, Yonghao Li, Xiaoning Gan, Chengyin Weng, Xisheng Fang, Guolong Liu

Open Access Original Paper

Citalopram, an antipsychotic agent, induces G1/G0 phase cell cycle arrest and promotes apoptosis in human laryngeal carcinoma HEP-2 cells

Mohammed Salama, Abeer Ali, Fawziya A. R. Ibrahim, Seham Elabd

Open Access Original Paper

Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment

Alaa Elmetwalli, Mohamed O. Abdel-Monem, Ali H. El-Far, Gehad S. Ghaith, Noaf Abdullah N. Albalawi, Jihan Hassan, Nadia F. Ismail, Tarek El-Sewedy, Mashael Mashal Alnamshan, Nouf K. ALaqeel, Ibtesam S. Al-Dhuayan, Mervat G. Hassan

Original Paper

Immunomodulatory effects of Diospyros peregrina fruit preparation (DFP) in non-small cell lung cancer (NSCLC) by utilizing dendritic cell-mediated antigen presentation and T helper (TH) cell differentiation

Nawaneetan Sriraman, Ankita Sarkar, Sohom Naskar, Nitika Mahajan, Oishi Mukherjee, R. Pradeep, Melvin George, Koustav Sarkar

Original Paper

Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line

Nazli Demirkiran, Bengusu Aydin, Melek Pehlivan, Zeynep Yuce, H. Ogun Sercan

Original Paper

Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer

Shahnaz Hosseinzadeh, Mahsa Imani, Farhad Pourfarzi, Narjes Jafari, Saeid AbedianKenari, Elham Safarzadeh

Original Paper

A novel α,β-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor

Weijia Zhao, Min Mo, Jia Yu, Sha Cheng, Guiping Long, Zhiqiong Luo, Wei Liang, Chen Yan, Heng Luo, Baofei Sun

Original Paper

Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma

Sohini Roy, Geetha Shanmugam, Sudeshna Rakshit, R. Pradeep, Melvin George, Koustav Sarkar

Original Paper

Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach

Ahad Amer Alsaiari, Amal F. Gharib, Maha Mahfouz Bakhuraysah, Amani A. Alrehaili, Shatha M. Algethami, Hayfa Ali Alsaif, Norah Al Harthi, Mohammed Ageeli Hakami

Review Article

Regulation of cancer progression by CK2: an emerging therapeutic target

Shakeel Hussain, Yilei Guo, Yu Huo, Juanjuan Shi, Yongzhong Hou

Review Article

Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review

Sandipan Dasgupta, Sakuntala Gayen, Tania Chakraborty, Naureen Afrose, Ranita Pal, Sutapa Mahata, Vilas Nasare, Souvik Roy

Review Article

Investigating the correlation between prominent viruses and hematological malignancies: a literature review

Arian Haghtalab, Milad Hejazi, Naeem Goharnia, Ali Yekanlou, Kousha Hazhir, Asma Barghi, Zahra Bazzaz, Iman Allahverdizadeh, Ataollah GhalibafSabbaghi

Review Aritcle

Increased V-ATPase activity can lead to chemo-resistance in oral squamous cell carcinoma via autophagy induction: new insights

Ahmadreza Lagzian, Marziye Askari, Melika Sadat Haeri, Nastaran Sheikhi, Sara Banihashemi, Mohsen Nabi-Afjadi, Yalda Malekzadegan

Review Article

Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies

Khubaib Ali, Muhammad Nabeel, Fatima Mohsin, Mehwish Iqtedar, Muhammad Islam, Muhammad Fawad Rasool, Furqan K. Hashmi, Syed Ahmed Hussain, Hamid Saeed

Review Article

Dual function of activated PPARγ by ligands on tumor growth and immunotherapy

Mingjun Chen, Huijie Wang, Qian Cui, Juanjuan Shi, Yongzhong Hou

Review Article

Liver cancer wars: plant-derived polyphenols strike back

Chengu Niu, Jing Zhang, Patrick I. Okolo 3rd

Review Article

The role of SWI/SNF complexes in digestive system neoplasms

Hanyun Liang, Xin Zheng, Xiao Zhang, Yan Zhang, Jie Zheng

Review Article

Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy

Abdur Rauf, Payal B. Joshi, Ahmed Olatunde, Nabia Hafeez, Zubair Ahmad, Hassan A. Hemeg, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Muthu Thiruvengadam, Dhivya Viswanathan, Govindasamy Rajakumar, Rekha Thiruvengadam

Review Article

Ferroptosis is an effective strategy for cancer therapy

Afrasyab Khan, Yu Huo, Yilei Guo, Juanjuan Shi, Yongzhong Hou

Review Article

Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives

Alborz Soroush, Siavash Pourhossein, Dorrin Hosseingholizadeh, Ahmed Hjazi, Reza Shahhosseini, Haniyeh Kavoosi, Nazgol Kermanshahi, Parisa Behnamrad, Nima Ghavamikia, Mehdi Dadashpour, Sepideh Karkon Shayan

Review Article

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Guangxun Yuan, Mengke Ye, Yixi Zhang, Xun Zeng

Open Access Correction

Correction to: Gingerol and/or sorafenib attenuates the DAB-induced HCC and hepatic portal vein dilatation via ATG4/CASP3 and COIIV/COX-2/NF-κB expression

Afrah Fatthi Salama, Ali H. El-Far, Esraa Ali Anbar, Sabry Ali El-Naggar, Rami M. Elshazli, Alaa Elmetwalli

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.